Sebelipase Alfa
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB11563 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | Scheie syndrome | KG + DL |
| 2 | Hurler syndrome | KG + DL |
| 3 | growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant | KG + DL |
| 4 | cholesteryl ester storage disease | KG + DL |
| 5 | Wolman disease with hypolipoproteinemia and acanthocytosis | KG + DL |
| 6 | Gaucher disease | KG + DL |
| 7 | lysosomal storage disease with skeletal involvement | KG + DL |
| 8 | autosomal ichthyosis syndrome with fatal disease course | KG + DL |
| 9 | Tay-Sachs disease | KG + DL |
| 10 | benign neoplasm of adrenal gland | KG + DL |
| 11 | adult Krabbe disease | KG + DL |
| 12 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 13 | Krabbe disease | KG + DL |
| 14 | cholesterol metabolism disease | KG + DL |
| 15 | metachromatic leukodystrophy | KG + DL |
| 16 | encephalopathy due to prosaposin deficiency | KG + DL |
| 17 | infantile neuronal ceroid lipofuscinosis | KG + DL |
| 18 | alpha-mannosidosis | KG + DL |
| 19 | proximal myopathy with extrapyramidal signs | KG + DL |
| 20 | infantile cerebellar-retinal degeneration | KG + DL |
| 21 | free sialic acid storage disease | KG + DL |
| 22 | Cushing disease due to pituitary adenoma | KG + DL |
| 23 | exocrine pancreatic insufficiency | KG + DL |
| 24 | Steel syndrome | KG + DL |
| 25 | familial encephalopathy with neuroserpin inclusion bodies | KG + DL |
| 26 | cerebrotendinous xanthomatosis | KG + DL |
| 27 | familial apolipoprotein C-II deficiency | KG + DL |
| 28 | adolescent/adult-onset epilepsy syndrome | KG + DL |
| 29 | fumaric aciduria | KG + DL |
| 30 | X-linked lymphoproliferative disease due to SH2D1A deficiency | KG + DL |
| 31 | myoclonic epilepsy, juvenile, susceptibility to | KG + DL |
| 32 | adolescence-adult electroclinical syndrome | KG + DL |
| 33 | Fabry disease | KG + DL |
| 34 | gangliosidosis | KG + DL |
| 35 | Sanfilippo syndrome | KG + DL |
| 36 | skeletal muscle disease | KG + DL |
| 37 | familial generalized lentiginosis | KG + DL |
| 38 | hyperphenylalaninemia due to DNAJC12 deficiency | KG + DL |
| 39 | dopa-responsive dystonia | KG + DL |
| 40 | lysosomal disease with hypertrophic cardiomyopathy | KG + DL |
| 41 | pyridoxine-dependent epilepsy | KG + DL |
| 42 | syndromic neurometabolic disease with X-linked intellectual disability | KG + DL |
| 43 | hypophosphatasia | KG + DL |
| 44 | inclusion myopathy | KG + DL |
| 45 | congenital cataract-hearing loss-severe developmental delay syndrome | KG + DL |
| 46 | oxoglutaricaciduria | KG + DL |
| 47 | coenzyme Q10 deficiency | KG + DL |
| 48 | mucosulfatidosis | KG + DL |
| 49 | eyelids malposition disorder | KG + DL |
| 50 | rhabdoid tumor | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.